Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is curable in about 40–50% of adult patients, however this is subject to ample variations owing to several host- and disease-related prognostic characteristics. Currently, the study of minimal residual disease (MRD) following induction and early consolidation thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Spinelli, Orietta, Tosi, Manuela, Peruta, Barbara, Guinea Montalvo, Marie Lorena, Maino, Elena, Scattolin, Anna Maria, Parolini, Margherita, Viero, Piera, Rambaldi, Alessandro, Bassan, Renato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165493/
https://www.ncbi.nlm.nih.gov/pubmed/25237475
http://dx.doi.org/10.4084/MJHID.2014.062
Descripción
Sumario:Acute lymphoblastic leukemia (ALL) is curable in about 40–50% of adult patients, however this is subject to ample variations owing to several host- and disease-related prognostic characteristics. Currently, the study of minimal residual disease (MRD) following induction and early consolidation therapy stands out as the most sensitive individual prognostic marker to define the risk of relapse following the achievement of remission, and ultimately that of treatment failure or success. Because substantial therapeutic advancement is now being achieved using intensified pediatric-type regimens, MRD analysis is especially useful to orientate stem cell transplantation choices. These strategic innovations are progressively leading to greater than 50% cure rates.

Ejemplares similares